NDA 214958 · Bristol
Sotyktu
Deucravacitinib · Oral · Tyrosine Kinase 2 Inhibitor
NovelCDER novel approval, Sep 9, 2022: To treat moderate-to-severe plaque psoriasis
Last checked: Nov 19, 2026Latest source record: Jun 30, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Sep 9, 2022
Approved uses
2
Original approval plus efficacy supplements
Registered trials
85
21 Phase 3, 15 recruiting
FAERS reports
2,976
619 serious, 46 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 30, 2026.
SOTYKTU is a tyrosine kinase 2 (TYK2) inhibitor indicated for: • the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. ( 1.1 ) Limitations of Use : Not recommended for use in combination with other potent immunosuppressants. • the treatment of active psoriatic arthritis in adults. ( 1.2 ) 1.1 Plaque Psoriasis SOTYKTU is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Limitations of Use : SOTYKTU is not recommended for use in combination with other potent immunosuppressants. 1.2 Psoriatic Arthritis SOTYKTU is indicated for the treatment of active psoriatic arthritis in adults.
Mechanism: Deucravacitinib is an inhibitor of tyrosine kinase 2 (TYK2). TYK2 is a member of the Janus kinase (JAK) family. Deucravacitinib binds to the regulatory domain of TYK2, stabilizing an inhibitory interaction between the regulatory and the catalytic domains of the enzyme. This results in allosteric inhibition of receptor-mediated activation of TYK2 and its downstream activation of Signal Transducers and Activators of Transcription (STATs) as shown in cell-based assays. JAK kinases, including TYK2, function as pairs of homo- or heterodimers in the JAK-STAT pathways. TYK2 pairs with JAK1 to...
Therapeutic areas: Immunology and inflammation
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 6, 2026 Supplement 2 · Efficacy LetterLabel
- Sep 9, 2022 Original approval · Type 1 - New Molecular Entity NovelLetterLabelReview
1 products under this application
- SOTYKTU · DEUCRAVACITINIB 6MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Deucravacitinib" as an intervention, any sponsor and status, largest first.
- Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)Pivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07116967 · 3,040 participants (planned) · Start Sep 22, 2025 · Primary completion Jan 16, 2031
Drug: Deucravacitinib; Ustekinumab · For: Plaque Psoriasis
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 411 sites in all
- Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study CompletersPivotal-lookingNot yet recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07791199 · 2,300 participants (planned) · Start Dec 31, 2026 · Primary completion Oct 31, 2030
Drug: Deucravacitinib · For: Systemic Lupus Erythematosus; Sjögren's Disease; Psoriasis and 1 more
- Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With PsoriasisPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT04036435 · 1,466 participants · Start Aug 12, 2019 · Primary completion Jul 21, 2026
Drug: BMS-986165; Placebo · For: Psoriasis
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 302 sites in all
- An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque PsoriasisPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT03611751 · 1,020 participants · Start Jul 26, 2018 · Primary completion Nov 29, 2020
Drug: BMS-986165; Apremilast · For: Psoriasis
Sites: Birmingham, Alabama; Phoenix, Arizona; Tempe, Arizona · 205 sites in all
- A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's SyndromePivotal-lookingActive, not recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05946941 · 774 participants · Start Sep 11, 2023 · Primary completion Nov 18, 2026
Drug: Deucravacitinib · For: Sjögren's Syndrome
Sites: Fullerton, California; La Palma, California; San Francisco, California · 199 sites in all
- A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque PsoriasisPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06143878 · 774 participants · Start Jan 17, 2024 · Primary completion Sep 17, 2024
Drug: JNJ-77242113; JNJ-77242113 Matching Placebo and 2 more · For: Plaque Psoriasis
Sites: Phoenix, Arizona; Scottsdale, Arizona; Fort Smith, Arkansas · 164 sites in all
- A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)Pivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06220604 · 731 participants · Start Mar 9, 2024 · Primary completion Nov 15, 2024
Drug: JNJ-77242113; JNJ-77242113 Matching Placebo and 2 more · For: Plaque Psoriasis
Sites: Phoenix, Arizona; Encinitas, California; Encino, California · 128 sites in all
- A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor TreatmentPivotal-lookingActive, not recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT04908189 · 729 participants · Start Jul 15, 2021 · Primary completion Nov 7, 2024
Drug: Deucravacitinib; Apremilast · For: Psoriatic Arthritis
Sites: Mountain Brook, Alabama; Sacramento, California; Whittier, California · 138 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective286
- acne255
- pruritus244
- rash206
- psoriasis190
- erythema171
- off label use120
- skin burning sensation88
- product dose omission issue83
- adverse event82
- headache82
- pain79
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 140 |
| 2023 | 1,053 |
| 2024 | 850 |
| 2025 | 579 |
| 2026 | 352 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Sotyktu (Deucravacitinib)
2024 spending
$62.2M
Beneficiaries
1,803
8,580 claims
Per beneficiary
$34,513
$216.75 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $1,499,644 |
| 2023 | $34,323,077 |
| 2024 | $62,226,384 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.
Morand E, Pike M, Merrill JT, et al. · Arthritis Rheumatol 2023 · Randomized Controlled Trial, Clinical Trial, Phase II
- Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials.
Gold LS, Armstrong AW, Bissonnette R, et al. · Lancet 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis.
Kerschbaumer A, Smolen JS, Ferreira RJO, et al. · Ann Rheum Dis 2024 · Systematic Review
- Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.
Armstrong AW, Gooderham M, Warren RB, et al. · J Am Acad Dermatol 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Guelimi R, et al. · Cochrane Database Syst Rev 2025 · Comparative Study, Network Meta-Analysis
- Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Guelimi R, et al. · Cochrane Database Syst Rev 2023 · Review, Research Support, Non-U.S. Gov't
Sponsor: Bristol Myers Squibb
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.